SFE Investment Counsel Has $2.95 Million Holdings in Pfizer Inc. $PFE

SFE Investment Counsel grew its position in shares of Pfizer Inc. (NYSE:PFE) by 33.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 122,530 shares of the biopharmaceutical company’s stock after acquiring an additional 30,975 shares during the quarter. SFE Investment Counsel’s holdings in Pfizer were worth $2,951,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after purchasing an additional 7,031,162 shares in the last quarter. State Street Corp raised its holdings in Pfizer by 0.5% during the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after buying an additional 1,357,756 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Pfizer by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock valued at $3,235,642,000 after buying an additional 1,184,728 shares in the last quarter. Morgan Stanley lifted its stake in shares of Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after buying an additional 14,342,946 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Pfizer during the fourth quarter valued at about $1,830,986,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Merck and Moderna reported positive Phase 3 melanoma results for their personalized mRNA cancer-vaccine combination with Keytruda, demonstrating improved recurrence-free survival. Pfizer is not directly involved, but the data lifted sentiment across mRNA and oncology companies and highlighted the potential value of Pfizer’s own cancer-vaccine ambitions. Pfizer Stock Rises Wednesday: What’s Going On?
• Positive Sentiment: Pfizer and Valneva received validation from the European Medicines Agency for their Lyme disease vaccine application, allowing the filing to proceed to full regulatory review after encouraging late-stage efficacy and safety results. Pfizer Gets EMA Lyme Vaccine Filing Validation
• Positive Sentiment: Unusually heavy call-option activity indicated increased speculative interest: investors bought 170,284 call options, roughly 47% above typical daily volume. This is a sentiment signal rather than a change to Pfizer’s fundamentals.
• Positive Sentiment: Pfizer’s potential monthly obesity treatment, berobenatide, could provide entry into the fast-growing GLP-1 market if clinical development and market-share objectives are achieved. Pfizer’s Obesity Push
• Neutral Sentiment: Merck’s increased investment in personalized cancer vaccines raises the competitive bar for Pfizer and BioNTech. The development validates the market opportunity but could make it harder for Pfizer to differentiate its pipeline. Merck Just Raised the Stakes for Pfizer’s Cancer Vaccine Ambitions
• Negative Sentiment: Investors continue to debate Pfizer’s looming patent cliff, which could pressure revenue as key products face loss-of-exclusivity risk. The stock’s relatively low valuation and dividend appeal may partly reflect these concerns. Pfizer: Still Cheap Valuation Meets a Looming Patent Cliff

Pfizer Stock Performance

PFE stock opened at $28.25 on Thursday. The firm has a market cap of $161.00 billion, a PE ratio of 37.17 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The business has a 50 day moving average of $25.23 and a 200-day moving average of $26.23. Pfizer Inc. has a 12-month low of $23.58 and a 12-month high of $28.75.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is 226.32%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on PFE shares. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a report on Monday, July 6th. Weiss Ratings downgraded Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday. BMO Capital Markets decreased their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Citigroup increased their price objective on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 29th. Finally, Wolfe Research restated an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.28.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.